Clinicopathological significance of SOX4 and epithelial-mesenchymal transition markers in patients with laryngeal squamous cell carcinoma
- PMID: 33761659
- PMCID: PMC9282127
- DOI: 10.1097/MD.0000000000025028
Clinicopathological significance of SOX4 and epithelial-mesenchymal transition markers in patients with laryngeal squamous cell carcinoma
Abstract
Background and aim: Sex-determining region-Y-related high-mobility-group box 4 (SOX4) is associated with the metastasis and prognosis of many cancer types. However, studies on the role of SOX4 in laryngeal squamous cell carcinoma (LSCC) are few, and hence the mechanism is unclear. Epithelial-mesenchymal transition (EMT) allows neoplastic cells to gain the plasticity and motility required for tumor progression and metastasis. This study aimed to analyze the relationship between SOX4 and EMT, and their relationship with clinicopathological factors and related prognosis.
Methods: Immunohistochemical staining was used to detect the positive expression of SOX4 protein, EMT-related transcription factor protein, and related marker protein in 127 LSCC tissue samples. At the same time, data on various parameters of clinical pathology and postoperative survival were collected.
Results: The positive expression rate of SOX4 and Slug in LSCC was related to pathological differentiation, lymphatic invasion, and pathological tumor node metastasis (TNM) of a tumor. The expression rates of ZEB1, Twist, E-cadherin, N-cadherin, and β-catenin in LSCC correlated with lymphatic invasion and pathological tumor node metastasis. The expression of SOX4, combined expression of SOX4 and ZEB1, and lymphatic invasion were independent prognostic factors for the total survival time of patients with LSCC.
Conclusions: In summary, SOX4 was vital in the LSCC EMT process, which might be mediated by transcription factor ZEB1. SOX4 and ZEB1 might serve as potential biomarkers of metastasis and prognosis, as well as promising therapeutic targets of LSCC.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Clinicopathological significance of SOX4 and epithelial-mesenchymal transition markers in patients with laryngeal squamous cell carcinoma.Auris Nasus Larynx. 2021 Dec;48(6):1167-1175. doi: 10.1016/j.anl.2021.04.013. Epub 2021 May 14. Auris Nasus Larynx. 2021. PMID: 34001394
-
MicroRNA-625 inhibits cell invasion and epithelial-mesenchymal transition by targeting SOX4 in laryngeal squamous cell carcinoma.Biosci Rep. 2019 Jan 22;39(1):BSR20181882. doi: 10.1042/BSR20181882. Print 2019 Jan 31. Biosci Rep. 2019. PMID: 30563928 Free PMC article. Retracted.
-
ZEB1 promotes the progression and metastasis of cervical squamous cell carcinoma via the promotion of epithelial-mesenchymal transition.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11258-67. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26617850 Free PMC article.
-
Transcriptional regulation of EMT transcription factors in cancer.Semin Cancer Biol. 2023 Dec;97:21-29. doi: 10.1016/j.semcancer.2023.10.001. Epub 2023 Oct 5. Semin Cancer Biol. 2023. PMID: 37802266 Review.
-
SOXC Transcription Factors as Diagnostic Biomarkers and Therapeutic Targets for Arthritis.Int J Mol Sci. 2023 Feb 20;24(4):4215. doi: 10.3390/ijms24044215. Int J Mol Sci. 2023. PMID: 36835620 Free PMC article. Review.
Cited by
-
Downregulation of long noncoding RNA HCP5/miR-216a-5p/ZEB1 axis inhibits the malignant biological function of laryngeal squamous cell carcinoma cells.Front Immunol. 2022 Sep 30;13:1022677. doi: 10.3389/fimmu.2022.1022677. eCollection 2022. Front Immunol. 2022. PMID: 36248798 Free PMC article.
-
Roles, molecular mechanisms, and signaling pathways of TMEMs in neurological diseases.Am J Transl Res. 2021 Dec 15;13(12):13273-13297. eCollection 2021. Am J Transl Res. 2021. PMID: 35035675 Free PMC article. Review.
-
Epithelial-to-Mesenchymal Transition and Neoangiogenesis in Laryngeal Squamous Cell Carcinoma.Cancers (Basel). 2021 Jul 3;13(13):3339. doi: 10.3390/cancers13133339. Cancers (Basel). 2021. PMID: 34283055 Free PMC article.
References
-
- Agra IM, Ferlito A, Takes RP, et al. . Diagnosis and treatment of recurrent laryngeal cancer following initial nonsurgical therapy. Head Neck 2012;34:727–35. - PubMed
-
- Steuer CE, El-Deiry M, Parks JR, et al. . An update on larynx cancer. CA Cancer J Clin 2017;67:31–50. - PubMed
-
- Ferlito A, Haigentz M, Jr, Bradley PJ, et al. . Causes of death of patients with laryngeal cancer. Eur Arch Otorhinolaryngol 2014;271:425–34. - PubMed
-
- Stros M, Launholt D, Grasser KD. The HMG-box: a versatile protein domain occurring in a wide variety of DNA-binding proteins. Cell Mol Life Sci 2007;64:2590–606. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
